NIBEC Co. Ltd Asset Resilience Ratio

Latest as of June 2026: 0.59%

NIBEC Co. Ltd asset resilience ratio. NIBEC Co. Ltd (138610) has an Asset Resilience Ratio of 0.59% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 138610 days of operational coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩381.07 Million
≈ $258.24K USD Cash + Short-term Investments

Total Assets

₩64.54 Billion
≈ $43.74 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of NIBEC Co. Ltd (2016–2025)

Asset resilience ratio of NIBEC Co. Ltd from 2016 to 2025. This chart shows how NIBEC Co. Ltd's Asset Resilience Ratio has changed over time. Read NIBEC Co. Ltd (138610) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down NIBEC Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of NIBEC Co. Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩381.07 Million 0.59%
Total Liquid Assets ₩381.07 Million 0.59%

Asset Resilience Insights

  • Limited Liquidity: NIBEC Co. Ltd maintains only 0.59% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

NIBEC Co. Ltd Industry Peers by Asset Resilience Ratio

Compare NIBEC Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Bavarian Nordic
CO:BAVA
Biotechnology 10.83%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

NIBEC Co. Ltd Asset Resilience Ratio by Year (2016–2025)

NIBEC Co. Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for NIBEC Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 2.04% ₩1.29 Billion
≈ $872.33K
₩63.00 Billion
≈ $42.70 Million
+0.87pp
2024-12-31 1.17% ₩730.00 Million
≈ $494.71K
₩62.45 Billion
≈ $42.32 Million
-7.96pp
2023-12-31 9.13% ₩6.10 Billion
≈ $4.13 Million
₩66.80 Billion
≈ $45.27 Million
-2.53pp
2022-12-31 11.66% ₩8.77 Billion
≈ $5.94 Million
₩75.20 Billion
≈ $50.96 Million
+4.64pp
2021-12-31 7.02% ₩3.74 Billion
≈ $2.54 Million
₩53.28 Billion
≈ $36.11 Million
-43.62pp
2020-12-31 50.64% ₩26.88 Billion
≈ $18.22 Million
₩53.08 Billion
≈ $35.97 Million
+23.91pp
2019-12-31 26.74% ₩9.56 Billion
≈ $6.48 Million
₩35.73 Billion
≈ $24.22 Million
+22.89pp
2018-12-31 3.85% ₩858.97 Million
≈ $582.11K
₩22.32 Billion
≈ $15.12 Million
-16.64pp
2017-12-31 20.49% ₩5.28 Billion
≈ $3.58 Million
₩25.75 Billion
≈ $17.45 Million
+0.37pp
2016-12-31 20.13% ₩4.62 Billion
≈ $3.13 Million
₩22.97 Billion
≈ $15.57 Million
--
pp = percentage points

About NIBEC Co. Ltd

KQ:138610 Korea Biotechnology
Market Cap
$102.23 Million
₩150.85 Billion KRW
Market Cap Rank
#18943 Global
#898 in Korea
Share Price
₩13270.00
Change (1 day)
+0.15%
52-Week Range
₩12200.00 - ₩52300.00
All Time High
₩55200.00
About

NIBEC Co., Ltd., a healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally. It offers dental ointment, peptide containing dental bone graft materials, regenerative biomaterials, tooth whitening, tooth desensitizer, herbal toothpaste, and cosmetic products. The company was founded in 2000 and is base… Read more